>>> Allergan preliminary 2018 guidance disappoints, but long-term outlook is opt

Allergan preliminary 2018 guidance disappoints, but long-term outlook is optimistic - Mizuho (170.56)
Mizuho notes the CEO noted at an investor conference that the company expects a 5% top-line growth CAGR from 2017-2022, which they believe could be reassuring to investors, who may opt to look beyond the 2018 numbers. Thus, the announcement could be clearing, and effectively reset expectations to a more achievable level for the year, with more optimism for the future. They also think that Allergan needs to beat its estimates in 2018, and therefore guidance is likely viewed as a low hurdle. They are less optimistic about the pipeline and don't think that 2018 pipeline catalysts will meaningfully help share momentum, and prefer to await more attractive entry points into the stock; Neutral.

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:
  • BGFV -17.2%, (Big 5 Sports reports 4Q17 revs of $243.2 mln (-8.% y/y); same store sales -9.4% y/y), ELF -7.8%, (e.l.f. Beauty guides FY17 in-line ), URBN -4.8%, (Urban Outfitters holiday comparable retail segment net sales increased 2%, driven by double-digit growth in the direct-to-consumer channel, partially offset by negative retail store sales) EXPR -3.5%, BBW -2.2%, APA -1.4%
Other news:
  • AMMA -9.8% (to offer combination of shares of common stock and warrants to purchase shares in firm-commitment underwritten public offering)
  • LUV -1% (Dec Traffic)
  • DKS -0.5% (following BGFV guidance)
Analyst comments:
  • UAA -3.7% (downgraded to Negative from Neutral at Susquehanna)
  • JKS -2.6% (initiated with a Sell at Goldman)
  • AKS -1.5% (downgraded to Hold from Buy at Jefferies)
  • JBLU -1.3% (downgraded to Underperform from Buy at BofA/Merrill)
  • ALL -1.1% (downgraded to Market Perform from Outperform at Wells Fargo)
  • ABB -1% (downgraded to Neutral from Buy at BofA/Merrill)
  • PAYX -1% (downgraded to Neutral from Buy at BofA/Merrill)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:
  • SHLM +5.5%, TGT +4%, STX +2.5%, (Seagate Tech expects to report Q2 revenue of approximately $2.9 billion vs $2.74 bln consensus), CFMS +2%, SFM +0.9%, (Sprouts Farmers Market expects FY17 EPS to be slightly above previous guidance; Sees Q4 SSS growth of +4.6%), LMNR +0.8%, DLR +0.7%
Other news:
  • PSTI +10.2% (FDA has cleared the Company's Expanded Access Program (EAP) for the use of its PLX-PAD cell treatment in patients with Critical Limb Ischemia)
  • BPT +9.8% (increases Q4 dividend payment to $1.2301519/unit from $0.6758286/unit)
  • ATUS +8.9% (ticking higher; Altice N.V. approved plans for the separation of Altice USA from Altice NV )
  • ILMN +8.8% (Illumina and Thermo Fisher Scientific sign commercial agreement that enables Illumina to sell Ion AmpliSeq technology; Illumina also announced the launch of the iSeq 100 Sequencing System)
  • AXON +8.7% (announces a correction to the data related to the Company's investigational drug nelotanserin previously reported in its January 8, 2018 press release), ADMS +3.9% (announced full commercial launch of GOCOVRI extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy)
  • SNOA +2.6% (receives three new United Arab Emirates regulatory approvals)
  • BLDP +1.7% (Ballard Power will discuss strategic direction and recent progress within the 'rapidly expanding' fuel cell and clean energy area at Needham conference on Jan 17)
  • FHN +1.7% (light volume; details Tax Cuts and Jobs Act impact - estimates reduction to fourth quarter earnings of approximately $95 million)
  • NETE +1.3% (files for 1,079,136 share common stock offering by Esousa Holdings)
  • INCY +1.3% (higher on light volume following JPM presentation)
  • PODD +1.1% (announces strategic alliance with Ascensia Diabetes Care by signing commercial agreement)
Analyst comments:
  • AAL +2.1% (upgraded to Buy from Underperform at BofA/Merrill)
  • KKR +2% (added to Conviction Buy List at Goldman)
  • TROW +1.6% (upgraded to Neutral from Sell at UBS)
  • CCL +1.1% (upgraded to Outperform from Neutral at Credit Suisse)
  • PYPL +0.9% (upgraded to Outperform from Market Perform at Cowen)

>>> T-Mobile US delivers 1.9 million Total Net Additions, 891,000 Postpaid Phone

T-Mobile US delivers 1.9 million Total Net Additions, 891,000 Postpaid Phone Net Additions with record low Q4 Postpaid Phone Churn
Preliminary Fourth Quarter 2017 Customer Highlights:
  • 1.9 million total net additions
  • 1.1 million branded postpaid net additions
  • 891,000 branded postpaid phone net additions
  • 149,000 branded prepaid net additions
  • Branded postpaid phone churn of 1.18%, down 10 basis points year-over-year
Approximately 7.0 million shares repurchased in 2017 at an average price per share of $63.34 for a total purchase price of $444 million - approximately 30% of total authorized amount of $1.5 billio

>>> US Early premarket gappers

Early premarket gappers
Gapping up:
  • BPT +9.8%, ILMN +7.9%, SHLM +5.5%, TGT +4.2%, ADMS +3.9%, TNDM +2.3%, STX +2.2%, ALKS +2.1%, CFMS +2%, ATUS +1.9%, BLDP +1.7%, FHN +1.7%, NETE +1.3%, BTI +0.9%, SFM +0.9%, LMNR +0.8%, INCY +0.7%, DLR +0.7%
Gapping down:
  • BGFV -17.2%, AMMA -9.8%, ELF -7.8%, URBN -4.8%, EXPR -3.5%, BBW -2.2%, AKS -2%, APA -1.4%, ALL -1.1%, ABB -1%

WSJ : $55 Billion Profit for Giant Asset Manager—the Swiss Central Bank

$55 Billion Profit for Giant Asset Manager—the Swiss Central Bank
SNB expects record profit on higher global equity and bond prices and a weaker Swiss franc

ZURICH—Switzerland got a lot wealthier in 2017, thanks to its central bank’s emergence as a major money manager with a near $800 billion portfolio of foreign stocks and bonds.

The Swiss National Bank said Tuesday it expects to report a record annual profit of 54 billion Swiss francs ($55 billion) for last year—a staggering sum equal to 8% of the country’s entire gross domestic product. By comparison, if the Federal Reserve were to run a profit of similar scale relative to the U.S. economy, it would be about $1.5 trillion. The Federal Reserve has earned an annual profit of around $100 billion in recent years.

But the Swiss National Bank can’t lock in its paper profits by selling chunks of its assets, for fear of lifting the franc’s value and hurting exports while weakening consumer prices. That will likely keep its balance sheet at the mercy of financial markets this year.

The SNB’s profit was lifted by a trio of positive forces: low bond yields preserved the value of its foreign bonds that account for 80% of its foreign reserves; higher stock prices raised the value of its equity holdings and the weaker Swiss currency made those foreign assets worth more in franc terms.

The euro strengthened nearly 10% against the franc last year. Euro-denominated assets are the largest currency holding of the SNB, followed by the dollar.

The SNB said 49 billion francs of its profits came from its foreign assets. Its gold holdings increased in value by about three billion francs last year, and its Swiss franc positions by two billion francs.

Switzerland’s central bank has accumulated about 760 billion francs in foreign bonds and stocks through years of foreign-exchange interventions, particularly during Europe’s debt crisis, in which it created francs and used them to purchase foreign assets in a bid to weaken the currency.

Other central banks like the Federal Reserve, European Central Bank and Bank of Japan have also amassed large portfolios consisting primarily of bonds. But those assets are denominated in their own currencies. What sets the SNB apart is that its balance sheet is comprised almost entirely of foreign assets, exposing it to huge foreign-exchange risk.

Things haven’t always gone the SNB’s way. In 2015, the central bank’s decision to abandon a ceiling on the franc’s value caused the franc to soar in value, leading to a 23 billion franc loss that year.

The Swiss can’t spend this latest windfall. Booking its profits would require the SNB to sell some of its foreign bonds and stocks that included nearly $3 billion in Apple Inc. stock and $1.5 billion in Facebook Inc. at the end of the third quarter. The SNB’s equity investments—which comprise 20% of its foreign assets—replicate broad indexes.

And while central banks like the Federal Reserve transfer most of their profits to their governments, the SNB is in the early stages of a five-year profit-sharing arrangement whereby the maximum amount it can transfer to the Swiss federal and regional governments is just two billion francs a year.

That agreement runs until 2020. It also pays a small amount—1.5 million francs annually—to its private shareholders. The SNB is one of the few central banks with listed shares. Its share price more than doubled last year, and was up 2% early Tuesday.

The SNB said it would allocate about five billion francs to its provisions that guard against future fluctuations in exchange rates. The rest of its paper profits will go to a distribution reserve to ensure that the SNB can still make future payouts even in the event of a loss.

FT : Hedge funds produce best returns in 4 years

Hedge funds produce best returns in 4 years
Strong performance from managers who bet on stocks restores optimism

The global hedge fund industry last year produced its best returns since 2013, driven by strong performances from managers who bet on stocks.

Advisers say it is too early to be sure this return to form will assuage investors’ concerns about high fees and mediocre long-term profits. But a cautious optimism has returned to the industry after the outflows of 2016 — the worst year for flows since the financial crisis — and many managers posted robust, or even eye-poppingly good, returns.

“In 2017 hedge funds as a strategy finally justified their cost of capital,” said Scott Warner, a partner at the fund of hedge funds Paamco. “But to really start to drive money back into the asset class, we’re going to have to see a more sustained period of performance.”

Funds that can make both positive and negative bets on stock price movements, known as long-short equity funds, were some of the best performers of the year, helping to retain money that investors had been rapidly shifting towards cheaper, passive and more liquid products.

Some of the biggest long-short equity shops had funds that returned double-digits last year. Some smaller managers did particularly well: Whale Rock Capital and Light Street Capital returned 36.2 and 38.6 per cent, respectively, off the rise of technology stocks including Alibaba.

Tiger Global, one of the largest long-short managers, had returned 27.5 per cent as of the end of November.

“There was really good stock selection both on the long and short side,” said Jon Hansen, a director of hedge funds at Cambridge Associates, an investment consulting firm. “When managers were right in 2017, they tended to be rewarded for that on both sides of the book.”

Activist funds performed strongly, too. TCI, the London-based activist, was up 28.2 per cent for the year. Marshall Wace, Lansdowne, Cevian Capital, Teleios Capital, Brenner West and Naya Capital all had funds with returns in double digits for 2017 as a whole.

Figures tallied by HFR, the research group, this week show that hedge funds across all strategies produced returns of 8.5 per cent in 2017, better than the 5.4 per cent recorded in 2016. Equities hedge funds — which include long-short funds, growth and value funds and sector-specific strategies — were up 13.2 per cent, their best showing in four years.


The revival in fortunes came just in time. Bob Leonard, a managing director at Credit Suisse’s investment bank and its global head of capital services, said equity long-short had been “on a lot of people’s watch lists” for possible redemptions.

But, while investors who are currently invested in equity long-short funds that outperformed are likely to stay, they are still unlikely to add to the allocation, he said. All equity funds were buoyed by rising stock valuations, as the S&P 500 rose 19 per cent last year.

“Some are thinking that equity valuations are getting a bit stretched, and no one knows when or how this ends, but some institutional investors are taking chips off the table,” Mr Leonard said.

“As long as investors continue to think or feel like we’re getting a bit pricey in the developed markets, strategies like global macro is top of mind,” he added, because these are funds that can shift money between whole markets. “If you’re going to add equity long-short, you as a manager need to really prove to us how this is going to be diversified and uncorrelated.”

Macro funds managed returns of just 2.3 per cent in 2017, according to HFR, but that was better than the 1.0 per cent of the previous year. Relative value funds, which trade mainly in the credit markets, returned 5.3 per cent, less than the 7.7 per cent in 2016.

Despite the industry’s overall higher returns of the past year, investors are still wary of hedge funds. The high fee structure — traditionally a 2 per cent fund management fee and a 20 per cent performance fee — came under fire.

Funds responded by reducing fees, and the money that still flowed into the sector was consolidated mostly at the largest funds. Hedge fund closures outpaced the number of funds that opened in 2017 for the third year in a row, claiming several veterans of the industry. John Griffin’s Blue Ridge Capital, Neil Chriss’s Hutchin Hill Capital and Eric Mindich’s Eton Park Capital all shuttered, while Paul Tudor Jones closed one of his funds.

Don Steinbrugge, chief executive of investment consultant Agecroft Partners, predicted that while the amount of money managed by the industry would continue to grow in 2018, the number of hedge funds closing down would also rise.

“The hedge fund industry remains oversaturated,” he said in a note to clients. “We believe approximately 90 per cent of all hedge funds do not justify their fees . . . Some large managers are simply too large to maintain an edge.”

After investors pulled $70bn from hedge funds in 2016, $2.9bn in fresh capital trickled in over the first nine months of 2017. A final figure for the year will be out later. Mr Warner said managers at Paamco are “not seeing huge investor demand to pile back in, but an abatement of the pressure to redeem has occurred.”

Added Mr Hansen: “We went through a stretch where there was a lot of negative sentiment about hedge funds. That seems to have abated.”